TYRA Tyra Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1863127 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-52.1%
TTM EPS YoY-39.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-34.9%
ROA-33.0%
ROIC (approx.)-63.3%
Asset turnover—
Leverage & solvency
Liabilities / assets4.8%
Debt / equity0.00x
Current ratio23.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $102.93M | $80.08M | $62.52M | $43.01M | $20.64M |
| SG&A expense | $29.83M | $24.10M | $17.43M | $15.92M | $5.65M |
| Operating income | -$132.76M | -$104.18M | -$79.94M | -$58.93M | -$26.29M |
| Income tax | $0 | $0 | $0 | $2,000 | $1,000 |
| Net income | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -$26.29M |
| EBITDA | -$132.22M | -$103.66M | -$79.59M | -$58.63M | -$26.15M |
| EPS (basic) | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 |
| EPS (diluted) | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 |
| Weighted avg. shares (diluted) | 59.60M | 57.22M | 42.70M | 41.88M | 13.78M |
| Balance sheet | |||||
| Cash & equivalents | $77.39M | $92.97M | $59.01M | $252.21M | $302.43M |
| Current assets | $265.45M | $347.46M | $211.67M | $257.29M | $304.06M |
| PP&E, net | $1.31M | $1.65M | $1.63M | $1.08M | $1.03M |
| Total assets | $282.61M | $363.56M | $225.86M | $266.18M | $306.70M |
| Current liabilities | $18.09M | $14.59M | $15.33M | $5.70M | $3.62M |
| Total liabilities | $23.43M | $20.41M | $21.59M | $8.35M | $4.96M |
| Shareholders' equity | $259.18M | $343.15M | $204.26M | $257.83M | $301.74M |
| Shares outstanding | 53.71M | 50.75M | 43.02M | 42.35M | 41.44M |
| Cash flow statement | |||||
| Operating cash flow | -$95.14M | -$69.77M | -$50.14M | -$50.28M | -$23.75M |
| Capital expenditure | $141,000 | $664,000 | $770,000 | $559,000 | $661,000 |
| Free cash flow | -$95.28M | -$70.44M | -$50.91M | -$50.84M | -$24.41M |
| Investing cash flow | $72.46M | -$98.40M | -$144.60M | -$559,000 | -$645,000 |
| Financing cash flow | $8.10M | $202.14M | $1.54M | $632,000 | $311.35M |
| Depreciation & amortization | $546,000 | $519,000 | $357,000 | $296,000 | $140,000 |
| Stock-based compensation | $28.01M | $22.80M | $13.53M | $10.59M | $2.89M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.